Angiogenesis induced by hepatocyte growth factor in non-infarcted myocardium and infarcted myocardium: up-regulation of essential transcription factor for angiogenesis, ets

被引:179
作者
Aoki, M
Morishita, R
Taniyama, Y
Kida, I
Moriguchi, A
Matsumoto, K
Nakamura, T
Kaneda, Y
Higaki, J
Ogihara, T
机构
[1] Osaka Univ, Sch Med, Div Gene Therapy Sci, Suita, Osaka 565, Japan
[2] Osaka Univ, Sch Med, Dept Geriatr Med, Suita, Osaka 565, Japan
[3] Osaka Univ, Sch Med, Biomed Res Ctr, Dept Oncol,Div Biochem, Suita, Osaka 565, Japan
关键词
hypoxia; gene transfer; HVJ (hemagglutinating virus of Japan); endothelial cell; ischemia; HGF;
D O I
10.1038/sj.gt.3301104
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The feasibility of a novel therapeutic strategy using angiogenic growth factors to expedite and/or augment collateral artery development has recently entered the realm of treatment of ischemic diseases. Hepatocyte growth factor (HGF) is a novel member of endothelium-specific growth factors whose mitogenic activity on endothelial cells is very potent. Although it has been demonstrated that HGF is a potential angiogenic growth factor in in vitro culture systems, there is no direct in vivo evidence for the angiogenic activity of HGF in physiological conditions. In this study, we hypothesized that transfection of HGF gene into infarcted myocardium could induce angiogenesis, potentially resulting in a beneficial response to hypoxia. Human HGF gene or control vector driven by the SR alpha promoter was transfected into rat myocardium by the HVJ-liposome method. Four days after in vivo transfection of human HGF gene, there was a marked increase in human immunoreactive HGF as compared with control vector (P < 0.01). In myocardium transfected with HGF vector a significant increase in PCNA-positive endothelial cells was observed while few PCNA-positive endothelial cells were detected in both control-vector-transfected and untreated myocardium. The number of vessels around the HGF injection sites was significantly increased as compared with control Vector or vehicle (P < 0.01). Angiogenic activity induced by the transfection of HGF vector was also confirmed by the activation of a transcription factor, ets, which is essential for angiogenesis. Furthermore, we studied the pathophysiological role of HGF in a myocardial infarction model. The concentration of endogenous HGF was significantly decreased in infarcted myocardium. Therefore, we hypothesized that transfection of HGF gene into infarcted myocardium could induce a beneficial response to the decreased endogenous HGF. indeed, transfection of human HGF into infarcted myocardium also resulted in a significant increase in the number of vessels (P < 0.01), accompanied by marked induction of ets binding activity and a significant increase in blood flow. Overall, the present results provide direct in vivo evidence for the induction of angiogenesis by transfection of the human HGF gene in rat non-infarcted and infarcted myocardium. The constant production of local HGF resulting from the transgene may be considered as an innovative therapeutic angiogenesis strategy for ischemic diseases such as myocardial infarction.
引用
收藏
页码:417 / 427
页数:11
相关论文
共 50 条
[1]   Efficient in vivo gene transfer into the heart in the rat myocardial infarction model using the HVJ (hemagglutinating virus of Japan) - Liposome method [J].
Aoki, M ;
Morishita, R ;
Muraishi, A ;
Moriguchi, A ;
Sugimoto, T ;
Maeda, K ;
Dzau, VJ ;
Kaneda, Y ;
Higaki, J ;
Ogihara, T .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1997, 29 (03) :949-959
[2]   Survival of grafts of genetically modified cardiac myocytes transfected with FITC-labeled oligodeoxynucleotides and the beta-galactosidase gene in the noninfarcted area, but not the myocardial infarcted area [J].
Aoki, M ;
Morishita, R ;
Higaki, J ;
Moriguchi, A ;
Hayashi, S ;
Matsushita, H ;
Kida, I ;
Tomita, N ;
Sawa, Y ;
Kaneda, Y ;
Ogihara, T .
GENE THERAPY, 1997, 4 (02) :120-127
[3]   In vivo transfer efficiency of antisense oligonucleotides into the myocardium using HVJ-liposome method [J].
Aoki, M ;
Morishita, R ;
Higaki, J ;
Moriguchi, A ;
Kida, I ;
Hayashi, S ;
Matsushita, H ;
Kaneda, Y ;
Ogihara, T .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 231 (03) :540-545
[4]   UP-REGULATION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR EXPRESSION INDUCED BY MYOCARDIAL-ISCHEMIA - IMPLICATIONS FOR CORONARY ANGIOGENESIS [J].
BANAI, S ;
SHWEIKI, D ;
PINSON, A ;
CHANDRA, M ;
LAZAROVICI, G ;
KESHET, E .
CARDIOVASCULAR RESEARCH, 1994, 28 (08) :1176-1179
[5]   HEPATOCYTE GROWTH-FACTOR IS A POTENT ANGIOGENIC FACTOR WHICH STIMULATES ENDOTHELIAL-CELL MOTILITY AND GROWTH [J].
BUSSOLINO, F ;
DIRENZO, MF ;
ZICHE, M ;
BOCCHIETTO, E ;
OLIVERO, M ;
NALDINI, L ;
GAUDINO, G ;
TAMAGNONE, L ;
COFFER, A ;
COMOGLIO, PM .
JOURNAL OF CELL BIOLOGY, 1992, 119 (03) :629-641
[6]  
Couffinhal T, 1998, AM J PATHOL, V152, P1667
[7]   Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences [J].
Gum, R ;
Lengyel, E ;
Juarez, J ;
Chen, JH ;
Sato, H ;
Seiki, M ;
Boyd, D .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (18) :10672-10680
[8]   RECENT ADVANCES IN THE APPLICATION OF GENE-THERAPY TO HUMAN-DISEASE [J].
HANANIA, EG ;
KAVANAGH, J ;
HORTOBAGYI, G ;
GILES, RE ;
CHAMPLIN, R ;
DEISSEROTH, AB .
AMERICAN JOURNAL OF MEDICINE, 1995, 99 (05) :537-552
[9]  
HARADA K, 1996, AM J PHYSIOL, V272, pH1791
[10]  
Hashimoto Etsuo, 1994, American Journal of Physiology, V267, pH1948